With the advent of the precision cancer therapy era, neoadjuvant therapy has become the standard therapy for certain types of breast cancer. Neoadjuvant therapy is a fundamental treatment plan implemented at the time of disease diagnosis, and its efficacy can guide the formulation of subsequent adjuvant therapy strategies. Building on the efficacy of neoadjuvant therapy and medication regimens, in conjunction with evidence-based medicine and healthcare policy, developing adjuvant therapy strategies for breast cancer following neoadjuvant therapy has the benefit of providing more precise treatment options for patients.
随着肿瘤精准治疗时代的到来，新辅助治疗已成为特定类别乳腺癌的标准治疗方案。新辅助治疗是在疾病确诊时开始制定的基本治疗方案，其治疗效果可为后续辅助治疗的方案制定提供指导。基于新辅助的治疗效果及用药方案，结合循证医学证据及医保政策，制定乳腺癌新辅助治疗后辅助治疗的分层策略，可为患者提供更加精准的治疗方案。.